5-Minute Check In: Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma

Guest: Dr. Christopher Huerter, Professor and Division Chief Dermatology at Creighton University School of MedicineBreakthrough treatments: Checkpoint inhibitors like Ipilimumab have changed the way we treat melanoma. Now, a new cutting-edge adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has shown promise in metastatic melanoma treatment trials. A new phase III trial compares TIL to Ipilimumab immunotherapy as first- or second-line treatment in patients with advanced melanoma with remarkable results.Article:  https://www.nejm.org/doi/full/10.1056/NEJMoa2210233